TABLE 1.
Demographic, clinical, and socioeconomic characteristics of the study population of patients with cancer, with and without COVID‐19
| COVID‐19 (N = 1267) | No COVID‐19 (N = 146 702) | ||
|---|---|---|---|
| Demographic characteristics | |||
| Age, Median (IQR) | 66 (55, 75) | 67 (57, 76) | |
| Age categories, N (%) | |||
| <60 | 182 (14%) | 19 263 (13%) | |
| 60‐69 | 415 (33%) | 42 963 (29%) | |
| ≥70 | 670 (53%) | 84 476 (58%) | |
| Sex, N (%) | |||
| Male | 539 (43%) | 62 650 (43%) | |
| Female | 728 (57%) | 84 049 (57%) | |
| Missing | 0 (0%) | 3 (0%) | |
| Race/ethnicity, N (%) | |||
| Non‐Hispanic white | 559 (44%) | 99 591 (68%) | |
| Non‐Hispanic black | 425 (34%) | 14 667 (10%) | |
| Hispanic/Latino | 54 (4%) | 3690 (3%) | |
| Asian/Native Hawaiian or Pacific Islander | 19 (1%) | 1489 (1%) | |
| Other or unknown | 210 (17%) | 27 265 (19%) | |
| Annual household income, median (IQR) | |||
| 0‐30 k | 189 (15%) | 6959 (5%) | |
| 30‐60 k | 723 (57%) | 80 005 (55%) | |
| 60‐100 k | 315 (25%) | 54 090 (37%) | |
| 100‐185 k | 34 (3%) | 4875 (3%) | |
| 185 k+ | 0 (0%) | 1 (0%) | |
| Missing | 6 (0%) | 772 (1%) | |
| Clinical characteristics | |||
| Comorbidities in the year prior to 2/1/2020, N (%) | |||
| Charlson Comorbidity Index | |||
| Median, IQR | 1.0 (0, 2.0) | 1.0 (0, 1.0) | |
| 0 | 426 (34%) | 67 969 (46%) | |
| 1 | 379 (30%) | 43 674 (30%) | |
| 2+ | 462 (36%) | 35 059 (24%) | |
| Hypertension | 411 (32%) | 39 901 (27%) | |
| Diabetes | 301 (24%) | 19 354 (13%) | |
| Chronic pulmonary disease | 141 (11%) | 11 680 (8%) | |
| Grade 3/4 chronic kidney disease | 125 (10%) | 9118 (6%) | |
| Renal failure | 179 (14%) | 11 771 (8%) | |
| Liver disease | 59 (5%) | 3755 (3%) | |
| Peripheral vascular disorders | 77 (6%) | 7125 (5%) | |
| Coagulopathy | 48 (4%) | 3282 (2%) | |
| Pulmonary circulation disorders | 48 (4%) | 2719 (2%) | |
| Obesity | 98 (8%) | 7207 (5%) | |
| HIV/AIDS | 5 (0%) | 209 (0%) | |
| Rheumatoid arthritis/collagen vascular diseases | 53 (4%) | 3371 (2%) | |
| Surgery in the year prior to 2/1/2020, N (%) | 461 (36%) | 41 176 (28%) | |
| Cancer‐related characteristics | |||
| Active cancers, N (%) | 719 (57%) | 69 924 (48%) | |
| History of cancer, N (%) | 548 (43%) | 76 778 (52%) | |
| Cancer type, N (%) | |||
| Hematological | 190 (15%) | 18 426 (13%) | |
| Breast | 171 (13%) | 23 576 (16%) | |
| Genitourinary | |||
| Prostate | 153 (12%) | 19 608 (13%) | |
| Other | 40 (3%) | 6971 (5%) | |
| Lung and respiratory | |||
| Lung | 80 (6%) | 6514 (4%) | |
| Other | 0 (0%) | 51 (0%) | |
| Gastrointestinal | |||
| Colorectal | 33 (3%) | 3394 (2%) | |
| Other | 74 (6%) | 7213 (5%) | |
| Abdominal | 4 (0%) | 708 (0%) | |
| Gynecological | 137 (11%) | 13 914 (9%) | |
| Bone and soft tissue | 46 (4%) | 4068 (3%) | |
| CNS and brain | 10 (1%) | 1207 (1%) | |
| Endocrine | 53 (4%) | 5491 (4%) | |
| Skin | 18 (1%) | 3619 (2%) | |
| Head and neck | 19 (1%) | 3144 (2%) | |
| Malignant, unknown site | 19 (1%) | 1286 (1%) | |
| Neoplasm, NOS | 220 (17%) | 27 460 (19%) | |
| Cancer treatment in the 30 days prior to 2/1/2020, N (%) | |||
| Immune checkpoint inhibitors | 12 (1%) | 624 (0%) | |
| Chemotherapy | 39 (3%) | 2310 (2%) | |
| Targeted therapies | 63 (5%) | 3887 (3%) | |
| Clinical endpoints | |||
| Mortality, N (%) | 173 (14%) | 3417 (2%) | |
| Hospital admissions, N (%) | 913 (72%) | 54 057 (37%) | |
| Invasive respiratory support, N (%) a | 138 (15%) | 790 (1%) | |
a
Among those for whom data were available.